OM1 Appoints Hunter Lane as Chief Product Officer

Lane to lead product and engineering strategy, driving innovation and growth in AI-powered real-world evidence and outcomes solutions for healthcare

BOSTON--(BUSINESS WIRE)--OM1, the leader in real-world evidence (RWE) generation and AI-driven insights for healthcare and life sciences, today announced the appointment of Hunter Lane as Chief Product Officer. In this role, Lane will lead the company’s Product and Engineering teams, overseeing the development and delivery of OM1’s rapidly growing portfolio of AI-driven evidence and outcomes solutions.

“Hunter’s track record of building category-defining platforms and delivering impact at scale makes him an ideal leader for our next stage of growth,” said Dr. Richard Gliklich, CEO and Founder of OM1. “His experience integrating AI and real-world data into clinical and research workflows aligns with OM1’s mission to improve health outcomes and accelerate innovation.”

Lane brings deep experience in health data innovation and product strategy, having most recently served as Senior Director of Product at Tempus AI. There, he launched the company’s flagship platform and was instrumental in scaling its genomics business from pre-revenue to $452 million in annual revenue. Under his leadership, Tempus built one of the largest real-world oncology datasets, driving research across 95% of the top 20 pharmaceutical companies.

“OM1 is uniquely positioned at the intersection of real-world data, AI, and patient outcomes,” said Lane. “I’m thrilled to join this exceptional team and help scale the next generation of solutions that will power smarter research, more equitable care, and better results for patients everywhere.”

Lane holds multiple patents in health data and AI, lectures on healthcare innovation at Northwestern University’s MBAi program, and has a degree in International Business from Loyola University Chicago.

About OM1

OM1 is pioneering cutting-edge healthcare innovation through its insights-driven technology and data. It specializes in personalized medicine, evidence generation, and real-world evidence (RWE) research powered by next-generation AI platforms, deep longitudinal data, and globally recognized thought leadership. OM1 is led by a diverse group of scientists, engineers, researchers, and clinicians with over 30 years of experience in RWE.